Edesa Biotech, Inc. announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of…
Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 17, 2026, Edesa Biotech, Inc. (the “Company”) announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (“ARDS”). The designation fo
